Geode Capital Management’s NeuroSense Therapeutics NRSN Stock Holding History

Geode Capital Management’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Hold	794	–	–	﹤0.01%	4412
2026 Q1	$12K	Hold	794	–	–	﹤0.01%	4483
2025 Q4	$12.2K	Hold	794	–	–	﹤0.01%	4422
2025 Q3	$19.8K	Hold	794	–	–	﹤0.01%	4418
2025 Q2	$30K	Hold	794	–	–	﹤0.01%	4306
2025 Q1	$14.6K	Hold	794	–	–	﹤0.01%	4404
2024 Q4	$19K	Buy	794 +196	+33%	+$4.51K	﹤0.01%	4391
2024 Q3	$15.2K	Hold	598	–	–	﹤0.01%	4426
2024 Q2	$13.4K	Hold	598	–	–	﹤0.01%	4516
2024 Q1	$21.8K	Hold	598	–	–	﹤0.01%	4473
2023 Q4	$9.39K	Buy	+598	New	+$7.95K	﹤0.01%	4596

Other funds holding NRSN

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Geode Capital Management's NRSN Position: Q2 2026 in Review

Geode Capital Management held its NeuroSense Therapeutics (NRSN) position steady in Q2 2026 at 794 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4412.

Geode Capital Management first reported a position in NRSN in Q4 2023 and has held it in 11 quarters since. The position peaked at $30K in Q2 2025. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

Geode Capital Management held 794 shares of NeuroSense Therapeutics worth $11.4K as of Q2 2026.
Geode Capital Management left its NeuroSense Therapeutics share count unchanged in Q2 2026.
NeuroSense Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4412 holding.
Geode Capital Management first reported a position in NeuroSense Therapeutics in Q4 2023 and has held it in 11 quarters since.
Geode Capital Management's NeuroSense Therapeutics position peaked at $30K in Q2 2025.
12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.